P01-249-Weight change and metabolic effects of asenapine in placebo- or olanzapine-controlled studies

Abstract

Introduction

Weight change and metabolic effects of atypical antipsychotics vary considerably.

Objective

Assess weight and metabolic effects of asenapine in adults.

Aim

Demonstrate that asenapine marketed doses are well tolerated compared with placebo or olanzapine.

Methods

Data were from pooled asenapine trials that used placebo (1748 patients; duration: 1−6 wk) and/or olanzapine (3430 patients; duration, 3−>100 wk) controls. Asenapine doses were 5 or 10 mg BID (2–20 mg BID in 2 studies); olanzapine doses were 5–20 mg QD. Post hoc inferential analyses based on ANOVA assessed change from baseline weight, body mass index, and fasting lipid and glucose levels.

Results

Table 1 summarizes the results.

[Change From Baseline Weight and Metabolic Paramete]

Discussion

These post hoc pooled analyses support published reports and suggest asenapine was associated with moderate weight gain and increased fasting triglyceride and glucose levels vs placebo, but lower propensity for weight gain or increased serum lipids (ie, triglycerides, low-density lipoprotein, and cholesterol) vs olanzapine.